Antihypertensives are a massive topic for the USMLE, and honestly, they're the bread and butter of internal medicine. We usually break them down into "The Big Four" primary classes and several secondary ones.

Let's start by looking at the main players and how they actually work to bring that blood pressure down. I'll pull up a clear summary of these mechanisms for you.

I've got a quick breakdown of the primary classes for you. Here's how they tackle the problem:

The Big Four: Mechanisms

1. ACE Inhibitors (e.g., Lisinopril) & ARBs (e.g., Losartan):

   • Mechanism: ACEi block the conversion of Angiotensin I to Angiotensin II. ARBs block the Angiotensin II receptor (AT1).
   • Effect: They cause vasodilation and decrease aldosterone secretion (reducing sodium/water retention).
   • High-Yield: ACEi can cause a dry cough due to increased bradykinin; ARBs don't. Both are teratogenic and can cause hyperkalemia.

2. Thiazide Diuretics (e.g., Chlorthalidone, HCTZ):

   • Mechanism: Inhibit the Na+/Cl- cotransporter in the distal convoluted tubule.
   • Effect: Increase sodium excretion, leading to decreased blood volume.
   • High-Yield: Watch out for the "hypo" side effects (hypokalemia, hyponatremia) and the "hyper" ones (hypercalcemia, hyperuricemia, hyperglycemia).

3. Calcium Channel Blockers (CCBs):

   • Dihydropyridines (e.g., Amlodipine): Act mainly on vascular smooth muscle → Vasodilation. (Side effect: Peripheral edema).
   • Non-dihydropyridines (e.g., Verapamil, Diltiazem): Act on the heart → Decrease heart rate and contractility.

4. Beta-Blockers (e.g., Metoprolol):

   • Mechanism: Block β1 receptors in the heart (decreasing CO) and kidneys (decreasing renin release).
   • Note: Usually not first-line for primary HTN unless there's a specific indication like heart failure or post-MI.

---

Step Therapy Approach (ACC/AHA Guidelines)

The management strategy depends heavily on the stage of hypertension and the patient's comorbidities. Let me find a clinical algorithm that maps out the step-by-step decision process.

The algorithm I found is a great look at the diagnostic side, but for the adult step therapy (ACC/AHA 2017 guidelines), here’s the high-yield breakdown you'll need for the USMLE:

1. Initial Management by Stage

• Normal (<120/80): Promote healthy lifestyle; recheck in 1 year.
• Elevated (120-129/<80): Lifestyle modifications; recheck in 3-6 months.
• Stage 1 (130-139 / 80-89):
  • If ASCVD risk <10%: Lifestyle only; recheck in 3-6 months.
  • If ASCVD risk >10% OR known CVD/DM/CKD: Lifestyle + 1 medication.
• Stage 2 (≥140/90): Lifestyle + 2 medications (usually from different classes).

2. Choosing the First-Line Drug

For most patients (non-Black), the "Big Four" are all fair game as initial monotherapy:

• Thiazide diuretics
• CCBs (Dihydropyridines like Amlodipine)
• ACE inhibitors or ARBs

3. Compelling Indications (The "Must-Knows")

This is where the exam gets tricky. You have to pick the right drug for the right patient:

• Black patients: Start with Thiazides or CCBs (ACEi are less effective as monotherapy here).
• CKD (with albuminuria) or Diabetes: ACEi or ARBs are mandatory for renal protection.
• Heart Failure (HFrEF): The "Triple Therapy" — ACEi/ARB + Beta-blocker + Spironolactone.
• Post-MI: Beta-blockers and ACEi/ARBs.
• Pregnancy: Use "He's Liked My Neonate" (Hydralazine, Labetalol, Methyldopa, Nifedipine). Avoid ACEi/ARBs!

---

Since there are so many classes and side effects to keep straight, would you like to try a quick game of Synapses? It’s a great way to practice grouping these drugs and their specific clinical pearls.